Cabozantinib (S)-malate Tablets for Renal Cell Carcinoma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for renal cell carcinoma, particularly those following anti-angiogenic therapy, have limited success in improving progression-free survival, objective response rate, and overall survival, with no agent demonstrating significant benefits across all three efficacy endpoints in clinical trials.
Innovation Solution
The use of cabozantinib, specifically its (S)-malate salt, as a tyrosine kinase inhibitor targeting MET, VEGF receptors, and AXL, administered as CABOMETYX® tablets, which provide a 19% increase in Cmax compared to the capsule formulation, demonstrating improved efficacy in extending progression-free survival, overall survival, and objective response rate in patients with advanced renal cell carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional VEGFR TKIs and mTOR inhibitors are used in patients who have received prior anti-angiogenic therapy, then treatment is provided, but no significant improvement is achieved in progression-free survival, objective response rate, and overall survival
Solution Approach 1:
The patent applies parameter changes by switching from conventional VEGFR TKIs and mTOR inhibitors to cabozantinib, a multi-kinase inhibitor with different pharmacokinetic parameters (oral bioavailability, half-life, Cmax). This parameter change enables simultaneous improvement in all three efficacy endpoints (PFS, ORR, OS) that previous therapies failed to achieve
Solution Approach 2:
Cabozantinib exhibits multi-functionality by inhibiting multiple kinase targets simultaneously (MET, VEGFR1-3, AXL, RET, ROS1, KIT, FLT3, TIE2), allowing it to address multiple pathological pathways in RCC. This universal mechanism enables the single agent to improve all three efficacy endpoints, unlike previous single-target therapies
2Ease of operation
If cabozantinib is administered as capsule formulation, then treatment is provided, but Cmax is lower compared to tablet formulation
Solution Approach 1:
The patent applies parameter changes by transitioning from capsule to tablet formulation, which alters the dissolution rate and absorption kinetics. The tablet formulation achieves a 19% higher Cmax compared to capsule formulation, optimizing the pharmacokinetic parameters for improved therapeutic efficacy
Data Source
AI summary
The present disclosure relates to a method of treating advanced renal cell carcinoma (RCC) in human patients who have received prior anti -angiogenic therapy using CABOMETYX, a kinase inhibitor.